RichardR.FurmanMD

PubMed

• 113 citations
  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
  John C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger
  Clinical Cancer Research. 2020-03-24
• 16 citations
  Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials
  Sue Richards, Michael Steurer
  Haematologica. 2011-12-01
• 65 citations
  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the...
  Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, Stephan Stilgenbauer, Paolo Ghia
  Biology of Blood and Marrow Transplantation. 2016-12-01

Journal Articles

• Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells  
  Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
• Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma  
  Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
• Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
  Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
• Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical Trials  
  Steven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
• Join now to see all

Abstracts/Posters

• CD79b Expression in Richter's Transformation
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Dual PI3K-_/_ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in RichterÍs Syndrome (RS)
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Richard R. Furman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all